Evinacumab
Evinacumab is a recombinant human monoclonal antibody that binds to and inhibits ANGPTL3 (angiopoietin-like protein 3), a liver-expressed protein that regulates lipid metabolism. It is primarily used as an adjunct therapy for homozygous familial hypercholesterolemia (HoFH) in patients who require additional lowering of LDL-C or other lipid parameters despite other treatments.
A monoclonal antibody that inhibits ANGPTL3 to lower cholesterol and triglycerides, used for homozygous familial hypercholesterolemia.
Key facts at a glance
- ATC
- C10AX17
- RxNorm
- 2478335
- Generic
- Evinacumab
- Class
- atc-c10
- Brands
- Evkeeza
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 15 mg/kg every 4 weeks
- Maximum
- consult physician
- Frequency
- once monthly
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 15 mg/kg every 4 weeks
- Maximum
- consult physician
- Frequency
- once monthly
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 15 mg/kg every 4 weeks
- Maximum
- consult physician
- Frequency
- once monthly
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
10 groupspregnancy
first trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks; discuss with healthcare provider
regular fetal monitoring recommended
Use with caution and monitor for adverse effects.
pregnancy
second trimesteravoid if possible
continue only if clearly needed; weigh benefits vs risks with cardiologist
regular fetal monitoring including ultrasounds
Use with caution and monitor for adverse effects.
pregnancy
third trimesteravoid near term if possible
discuss timing of last dose with healthcare provider; consider risks of continued use
fetal monitoring and assessment of placental function
Use with caution and monitor for adverse effects.
lactation
breastfeedingno specific adjustment
discontinue breastfeeding or avoid use; decision should be made weighing benefits and risks
monitor infant for immune system effects
geriatric
elderly 65 and olderno dose adjustment required
use standard dosing; monitor cardiovascular status
regular monitoring of lipid levels and cardiovascular function
pediatric_age
adolescents 12 to 17no dose adjustment
approved for patients 12 years and older with homozygous familial hypercholesterolemia
regular lipid panel monitoring and liver function tests
renal_impairment
mild to moderateno dose adjustment required
no renal dose adjustment needed; monoclonal antibodies not renally cleared
routine renal function monitoring
renal_impairment
severeuse with caution
limited data in severe renal impairment; monitor closely
enhanced renal function monitoring
Use with caution and monitor for adverse effects.
hepatic_impairment
mildno dose adjustment required
no adjustment needed for mild hepatic impairment
routine liver function monitoring
hepatic_impairment
moderate to severeuse with caution
limited data in moderate to severe hepatic impairment; benefits vs risks must be assessed
regular liver function tests and monitoring
Use with caution and monitor for adverse effects.
Statistics and clinical data
Drug class
Classification as a monoclonal antibody targeting ANGPTL3
FDA approval year
FDA approval date for Evkeeza
Indication
Primary therapeutic indication
Mechanism of action
Pharmacological mechanism of action
Evinacumab is indicated as an adjunct to other lipid-lowering therapies (such as statins, PCSK9 inhibitors, and LDL apheresis) for the treatment of adult and pediatric patients 12 years and older with homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder causing severely elevated LDL cholesterol levels.
Evinacumab is a fully human IgG2 monoclonal antibody that binds to and inhibits ANGPTL3. By blocking ANGPTL3, it increases the activity of lipoprotein lipase and endothelial lipase, leading to reduced triglycerides and LDL cholesterol levels. This mechanism is independent of LDL receptor activity, making it effective even in patients with limited LDL receptor function.
Administered as an intravenous infusion every 4 weeks. Common side effects may include nasopharyngitis, influenza-like illness, dizziness, and back pain. It should be used with caution in patients with known hypersensitivity. Pregnancy and breastfeeding should be carefully considered, as effects on the fetus are not fully established.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy